AU2010298256B2 - Novel NPR-B agonists - Google Patents

Novel NPR-B agonists Download PDF

Info

Publication number
AU2010298256B2
AU2010298256B2 AU2010298256A AU2010298256A AU2010298256B2 AU 2010298256 B2 AU2010298256 B2 AU 2010298256B2 AU 2010298256 A AU2010298256 A AU 2010298256A AU 2010298256 A AU2010298256 A AU 2010298256A AU 2010298256 B2 AU2010298256 B2 AU 2010298256B2
Authority
AU
Australia
Prior art keywords
leu
arg
asp
occ
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010298256A
Other languages
English (en)
Other versions
AU2010298256A1 (en
Inventor
Heiko Hawlisch
Mark R. Hellberg
Gerd Hummel
Tobias Knaute
Frank Osterkamp
Ulf Reimer
Ulrich Reineke
Uwe Richter
Bernadett Simon
Edgar Specker
Markus Woischnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43781057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010298256(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2010298256A1 publication Critical patent/AU2010298256A1/en
Assigned to SHIRE ORPHAN THERAPIES GMBH reassignment SHIRE ORPHAN THERAPIES GMBH Request for Assignment Assignors: ALCON RESEARCH, LTD.
Application granted granted Critical
Publication of AU2010298256B2 publication Critical patent/AU2010298256B2/en
Priority to AU2015255299A priority Critical patent/AU2015255299B2/en
Priority to AU2018202731A priority patent/AU2018202731A1/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: SHIRE ORPHAN THERAPIES GMBH
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2010298256A 2009-09-25 2010-09-23 Novel NPR-B agonists Ceased AU2010298256B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2015255299A AU2015255299B2 (en) 2009-09-25 2015-11-13 Novel npr-b agonists
AU2018202731A AU2018202731A1 (en) 2009-09-25 2018-04-19 Novel npr-b agonists

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24596009P 2009-09-25 2009-09-25
US61/245,960 2009-09-25
PCT/US2010/049912 WO2011038061A2 (en) 2009-09-25 2010-09-23 Novel npr-b agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015255299A Division AU2015255299B2 (en) 2009-09-25 2015-11-13 Novel npr-b agonists

Publications (2)

Publication Number Publication Date
AU2010298256A1 AU2010298256A1 (en) 2012-04-12
AU2010298256B2 true AU2010298256B2 (en) 2015-08-13

Family

ID=43781057

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010298256A Ceased AU2010298256B2 (en) 2009-09-25 2010-09-23 Novel NPR-B agonists

Country Status (17)

Country Link
US (5) US8546523B2 (enExample)
EP (1) EP2480247B1 (enExample)
JP (3) JP5893561B2 (enExample)
KR (3) KR20180049198A (enExample)
CN (2) CN102548574B (enExample)
AR (1) AR078445A1 (enExample)
AU (1) AU2010298256B2 (enExample)
BR (1) BR112012006579A2 (enExample)
CA (1) CA2773949C (enExample)
CL (2) CL2012000715A1 (enExample)
MX (3) MX2012003398A (enExample)
PH (1) PH12012500562A1 (enExample)
RU (3) RU2636738C2 (enExample)
TW (2) TWI577384B (enExample)
UY (1) UY32902A (enExample)
WO (1) WO2011038061A2 (enExample)
ZA (3) ZA201201630B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732406B2 (en) 2005-04-07 2010-06-08 Cardiopep Pharma Gmbh Use of natriuretic peptide for treating heart failure
JP5345532B2 (ja) * 2006-08-02 2013-11-20 ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ Ｌｃｔ中毒に対する医薬品
PH12012500562A1 (en) 2009-09-25 2012-10-22 Takeda Pharmaceuticals Co Novel npr-b antagonists
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists
CA2853204A1 (en) * 2011-12-16 2013-06-20 Kalos Therapeutics, Inc. Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases
NZ710246A (en) * 2013-01-25 2016-11-25 Cardiorentis Ltd Methods of treating cardiovasular indications
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
EP3576770A1 (en) * 2017-02-01 2019-12-11 Shire Human Genetic Therapies, Inc. Compounds and compositions for the treatment of ophthalmic disorders
CA3056433A1 (en) 2017-03-22 2018-09-27 Pharmain Corporation Npra agonists, compositions, and uses thereof
US20210121534A1 (en) * 2018-06-19 2021-04-29 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
EP3880685B1 (en) * 2018-11-16 2025-06-18 Arcus Biosciences, Inc. Inhibitors of arg1 and/or arg2
US20230416328A1 (en) * 2020-06-12 2023-12-28 Hirofumi Tachibana C-Type Natriuretic Peptides and Methods Thereof in Treating Acute Lung Injury
KR102677730B1 (ko) * 2023-03-27 2024-06-27 나인바이오팜 주식회사 지방 분해 효능을 갖는 펩타이드 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080153747A1 (en) * 2004-07-15 2008-06-26 The University Of Queensland Proteinaceous compounds and uses therefor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
EP0323740A3 (en) * 1987-12-24 1990-12-12 California Biotechnology, Inc. Linear analogs of atrial natriuretic peptides
JP2848411B2 (ja) * 1988-08-18 1999-01-20 サイオス インコーポレイテッド 心房性ナトリウム利尿ペプチドクリアランス阻害剤
EP1118329A4 (en) 1998-09-28 2004-12-15 Santen Pharmaceutical Co Ltd LACRYMAL SECRETION PROMOTERS OR OPHTHALMOLOGICAL DROPS CONTAINING NATRIURETIC PEPTIDES AS ACTIVE INGREDIENTS FOR TREATING KERATOCONJUNCTIVITY
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
WO2007034498A1 (en) * 2005-09-26 2007-03-29 Compugen Ltd. Atrial natriuretic peptide (anp) splice variants and methods of using same
CA2625600A1 (en) * 2005-10-14 2007-04-26 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
AU2007233116B2 (en) * 2006-03-30 2013-05-09 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
AU2007233123A1 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
AR069409A1 (es) * 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
PH12012500562A1 (en) 2009-09-25 2012-10-22 Takeda Pharmaceuticals Co Novel npr-b antagonists
US8551938B2 (en) 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080153747A1 (en) * 2004-07-15 2008-06-26 The University Of Queensland Proteinaceous compounds and uses therefor

Also Published As

Publication number Publication date
EP2480247A2 (en) 2012-08-01
US20160194357A1 (en) 2016-07-07
KR101768661B1 (ko) 2017-08-16
TWI577384B (zh) 2017-04-11
UY32902A (es) 2011-02-28
EP2480247A4 (en) 2013-09-04
AU2010298256A1 (en) 2012-04-12
ZA201702958B (en) 2018-08-29
WO2011038061A2 (en) 2011-03-31
JP2017137362A (ja) 2017-08-10
KR20180049198A (ko) 2018-05-10
US20110077381A1 (en) 2011-03-31
MX2012003398A (es) 2012-04-10
US20170313743A1 (en) 2017-11-02
JP6211032B2 (ja) 2017-10-11
US20180334477A1 (en) 2018-11-22
RU2012116531A (ru) 2013-10-27
CA2773949A1 (en) 2011-03-31
RU2015124607A (ru) 2015-12-10
CA2773949C (en) 2020-11-03
KR101854820B1 (ko) 2018-05-04
KR20170094564A (ko) 2017-08-18
CL2017001190A1 (es) 2017-12-01
US9169293B2 (en) 2015-10-27
CL2012000715A1 (es) 2012-11-30
TWI625126B (zh) 2018-06-01
BR112012006579A2 (pt) 2016-11-22
CN102548574B (zh) 2016-03-23
RU2017139870A3 (enExample) 2019-05-16
MX354005B (es) 2018-02-08
ZA201201630B (en) 2014-05-28
RU2557290C2 (ru) 2015-07-20
US8546523B2 (en) 2013-10-01
US20130345394A1 (en) 2013-12-26
KR20120091110A (ko) 2012-08-17
EP2480247B1 (en) 2020-02-12
PH12012500562A1 (en) 2012-10-22
AR078445A1 (es) 2011-11-09
CN105732767A (zh) 2016-07-06
WO2011038061A3 (en) 2011-07-28
US9745344B2 (en) 2017-08-29
ZA201401625B (en) 2018-08-25
MX370645B (es) 2019-12-19
JP2013505937A (ja) 2013-02-21
US10196423B2 (en) 2019-02-05
JP5893561B2 (ja) 2016-03-23
JP2015131856A (ja) 2015-07-23
RU2017139870A (ru) 2019-05-16
RU2636738C2 (ru) 2017-11-28
CN102548574A (zh) 2012-07-04
US9982016B2 (en) 2018-05-29
TW201110974A (en) 2011-04-01
TW201630619A (zh) 2016-09-01

Similar Documents

Publication Publication Date Title
US10196423B2 (en) NPR-B agonists
US8551938B2 (en) NPR-B agonists
WO2011075471A2 (en) Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
US20180094029A1 (en) Methods of treating ophthalmic diseases using npr-b agonists
US9458198B1 (en) Cyclic peptide-based NPR-B agonists
AU2015255299B2 (en) Novel npr-b agonists
HK1173070B (en) Novel npr-b agonists
HK1173070A (en) Novel npr-b agonists
HK1226800A1 (en) Novel npr-b agonists
HK1226800A (en) Novel npr-b agonists

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SHIRE ORPHAN THERAPIES GMBH

Free format text: FORMER APPLICANT(S): ALCON RESEARCH, LTD.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): SHIRE ORPHAN THERAPIES GMBH

MK14 Patent ceased section 143(a) (annual fees not paid) or expired